UCA1 and non-small cell lung carcinoma: Furthermore, UCA1 knockdown restored sensitivity to gefitinib in acquired-resistant NSCLC cells without the T790M mutation, and inhibited the activation of the AKT/mTOR pathway and epithelial-mesenchymal transition.